Skip to main content

Table 2 Comparison of liver function, renal function and performance status after PSE between the two groups

From: Efficacy and safety of heparin plus dexamethasone after partial splenic embolization for liver cirrhosis with massive splenomegaly

 

Group

Chi-square tests (P value)

t-test (P value)

PSE + Hep + DEX group (N = 54)

PSE group (N = 62)

Post-Treatment ECOG

0

Count (%)

19 (35.2%)

29 (46.8%)

0.260

 
 

1

Count (%)

30 (55.6%)

25 (40.3%)

  
 

2

Count (%)

5 (9.2%)

8 (12.9%)

  

Post-treatment liver function

Child A

Count (%)

43 (79.6%)

49 (79.0%)

0.937

 
 

Child B

Count (%)

11 (20.4%)

13 (21.0%)

  

Post-treatment bilirubin (μmol/L)

Mean ± SD

 

15.2 ± 5.1

13.8 ± 5.5

 

0.163

Post-treatment Albumin (g/L)

Mean ± SD

 

34.42 ± 3.06

33.58 ± 2.99

 

0.139

Post-treatment BUN (mmol/L)

Mean ± SD

 

5.96 ± 1.48

6.15 ± 1.49

 

0.512

Post-Treatment Cr (μmol/L)

Mean ± SD

 

72.2 ± 19.5

76.1 ± 20.9

 

0.309

Tests of Normality

 

Group

Kolmogorov–Smirnova

  

P value

Post-treatment bilirubin (μmol/L)

PSE + Hep + DEX group

0.218

 

PSE group

0.201

Post-treatment Albumin (g/L)

PSE + Hep + DEX group

0.132

 

PSE group

0.097

Post-treatment BUN (mmol/L)

PSE + Hep + DEX group

0.324

 

PSE group

0.166

Post-Treatment Cr (μmol/L)

PSE + Hep + DEX group

0.253

 

PSE group

0.107

  1. aLilliefors significance correction